These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 14518756)

  • 21. Charles Bonnet syndrome precipitated by brimonidine tartrate eye drops.
    Tomsak RL; Zaret CR; Weidenthal D
    Br J Ophthalmol; 2003 Jul; 87(7):917. PubMed ID: 12812898
    [No Abstract]   [Full Text] [Related]  

  • 22. Allergic reactions to brimonidine in patients treated for glaucoma.
    Blondeau P; Rousseau JA
    Can J Ophthalmol; 2002 Feb; 37(1):21-6. PubMed ID: 11865954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
    Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selectivity of site of action and systemic effects of topical alpha agonists.
    Robin AL; Burnstein Y
    Curr Opin Ophthalmol; 1998 Apr; 9(2):30-3. PubMed ID: 10180510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dilute brimonidine to improve patient comfort and subconjunctival hemorrhage after LASIK.
    Pasquali TA; Aufderheide A; Brinton JP; Avila MR; Stahl ED; Durrie DS
    J Refract Surg; 2013 Jul; 29(7):469-75. PubMed ID: 23820229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The teardrop sign: a rare dermatological reaction to brimonidine.
    Scruggs JT; Whiteside-Michel J; Brodsky MC
    Br J Ophthalmol; 2000 Jun; 84(6):671-2. PubMed ID: 10896417
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans.
    Schadlu R; Maus TL; Nau CB; Brubaker RF
    Arch Ophthalmol; 1998 Nov; 116(11):1441-4. PubMed ID: 9823343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Failure of naloxone to reverse brimonidine-induced coma in an infant.
    Sztajnbok J
    J Pediatr; 2002 Apr; 140(4):485-6; author reply 486. PubMed ID: 12006970
    [No Abstract]   [Full Text] [Related]  

  • 29. Systemic side effects of ophthalmic drops.
    Levy Y; Zadok D
    Clin Pediatr (Phila); 2004; 43(1):99-101. PubMed ID: 14968900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brimonidine tartrate: a one-month dose response study.
    Derick RJ; Robin AL; Walters TR; Barnebey HS; Choplin N; Schuman J; Kelley EP; Chen K; Stoecker JF
    Ophthalmology; 1997 Jan; 104(1):131-6. PubMed ID: 9022117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma.
    Korsch E; Grote A; Seybold M; Soditt V
    Eur J Pediatr; 1999 Aug; 158(8):685. PubMed ID: 10445353
    [No Abstract]   [Full Text] [Related]  

  • 32. Brimonidine and pupillary diameter.
    Mastropasqua L; Carpineto P; Ciancaglini M
    Ophthalmology; 1998 Aug; 105(8):1352-3. PubMed ID: 9709738
    [No Abstract]   [Full Text] [Related]  

  • 33. Is brimonidine ophthalmic a safe therapy for infants?
    Daubert GP
    J Clin Pharm Ther; 2006 Jun; 31(3):289-92. PubMed ID: 16789995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A paradoxical ocular effect of brimonidine.
    Mushtaq B; Sardar J; Matthews TD
    Am J Ophthalmol; 2003 Jan; 135(1):102-3. PubMed ID: 12504711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversible cicatricial ectropion precipitated by topical brimonidine eye drops.
    Aristodemou P; Baer R
    Ophthalmic Plast Reconstr Surg; 2008; 24(1):57-8. PubMed ID: 18209648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Anterior uveitis and topical brimonidine: a case report].
    Velasque L; Ducousso F; Pernod L; Vignal R; Deral V
    J Fr Ophtalmol; 2004 Dec; 27(10):1150-2. PubMed ID: 15687926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of brimonidine tartrate 0.2% ophthalmic solution in reducing halos after laser in situ keratomileusis.
    Lee JH; You YS; Choe CM; Lee ES
    J Cataract Refract Surg; 2008 Jun; 34(6):963-7. PubMed ID: 18499002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II.
    Melamed S; David R
    Clin Ther; 2000 Jan; 22(1):103-11. PubMed ID: 10688394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
    Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
    Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III.
    Serle JB
    Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S39-47. PubMed ID: 8970248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.